Literature DB >> 30311626

Incidence, risk factors and outcomes of malignancies after kidney transplantation in Singapore: a 12-year experience.

Su Hooi Teo1, Kian-Guan Lee1, Gek Hsiang Lim2, Si Xuan Koo3, Maria Erika Ramirez1, Khuan Yew Chow2, Terence Kee1.   

Abstract

INTRODUCTION: Data on malignancy after kidney transplantation (KTX) is limited in our region, leading to challenges in the care of renal allograft recipients. We aimed to examine the epidemiology, risk factors and outcomes of post-KTX patients.
METHODS: A retrospective cohort study was conducted of 491 patients who underwent KTX from 1 January 2000 to 31 December 2011. Data linkage analysis was done between our centre and the National Registry of Diseases Office to determine the standardised incidence ratio (SIR), standardised mortality ratio (SMR) and risk factors for malignancy after KTX.
RESULTS: 31 patients (61.3% male) developed malignancy during this period, and their median age at diagnosis was 50 (range 18-65) years. Median time to malignancy diagnosis was 2.6 (range 0.3-7.9) years, with cumulative incidence of 1%, 4% and 10% at one, five and ten years, respectively. The commonest malignancy type was lymphoma, followed by kidney cancer, colorectal cancer and malignancy of the male genital organs. Multivariate analysis identified cyclosporine use as an independent risk factor for malignancy. Compared to the general population, KTX recipients had higher malignancy and mortality rates after malignancy diagnosis (SIR 3.36; SMR 9.45). Survival rates for KTX recipients with malignancy versus those without malignancy were 100%, 93% and 64% versus 97%, 93% and 83% at one, five and ten years, respectively.
CONCLUSION: KTX was associated with higher mortality and incidence of malignancy. Newer immunosuppressive agents and induction therapies were not found to be risk factors for malignancy, possibly due to our relatively small sample size. Copyright: © Singapore Medical Association.

Entities:  

Keywords:  kidney transplantation; malignancy; outcomes; risk factors

Mesh:

Year:  2018        PMID: 30311626      PMCID: PMC6535454          DOI: 10.11622/smedj.2018122

Source DB:  PubMed          Journal:  Singapore Med J        ISSN: 0037-5675            Impact factor:   1.858


  34 in total

1.  Spectrum of malignancies in Asian renal allograft recipients.

Authors:  S Zinna; A Vathsala; K T Woo
Journal:  Transplant Proc       Date:  2000-11       Impact factor: 1.066

2.  De novo malignancies after kidney and liver transplantations: experience on 582 consecutive cases.

Authors:  U Baccarani; G L Adani; D Montanaro; A Risaliti; D Lorenzin; C Avellini; P Tulissi; M Groppuzzo; G Currò; F Luvisetto; A Beltrami; V Bresadola; P L Viale; F Bresadola
Journal:  Transplant Proc       Date:  2006-05       Impact factor: 1.066

3.  Cancer incidence before and after kidney transplantation.

Authors:  Claire M Vajdic; Stephen P McDonald; Margaret R E McCredie; Marina T van Leeuwen; John H Stewart; Matthew Law; Jeremy R Chapman; Angela C Webster; John M Kaldor; Andrew E Grulich
Journal:  JAMA       Date:  2006-12-20       Impact factor: 56.272

4.  Effect of cyclosporin A on DNA repair and cancer incidence in kidney transplant recipients.

Authors:  M Herman; T Weinstein; A Korzets; A Chagnac; Y Ori; D Zevin; T Malachi; U Gafter
Journal:  J Lab Clin Med       Date:  2001-01

Review 5.  Malignancy after transplantation.

Authors:  Joseph F Buell; Thomas G Gross; E Steve Woodle
Journal:  Transplantation       Date:  2005-10-15       Impact factor: 4.939

6.  Cyclosporine induces cancer progression by a cell-autonomous mechanism.

Authors:  M Hojo; T Morimoto; M Maluccio; T Asano; K Morimoto; M Lagman; T Shimbo; M Suthanthiran
Journal:  Nature       Date:  1999-02-11       Impact factor: 49.962

7.  Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients.

Authors:  Rami T Bustami; Akinlolu O Ojo; Robert A Wolfe; Robert M Merion; William M Bennett; Suzanne V McDiarmid; Alan B Leichtman; Philip J Held; Friedrich K Port
Journal:  Am J Transplant       Date:  2004-01       Impact factor: 8.086

8.  Renal transplantation in Singapore.

Authors:  A Vathsala; Khuan Yew Chow
Journal:  Ann Acad Med Singapore       Date:  2009-04       Impact factor: 2.473

9.  Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials.

Authors:  Angela C Webster; E Geoffrey Playford; Gail Higgins; Jeremy R Chapman; Jonathan C Craig
Journal:  Transplantation       Date:  2004-01-27       Impact factor: 4.939

10.  Identifying high risk groups and quantifying absolute risk of cancer after kidney transplantation: a cohort study of 15,183 recipients.

Authors:  A C Webster; J C Craig; J M Simpson; M P Jones; J R Chapman
Journal:  Am J Transplant       Date:  2007-07-19       Impact factor: 8.086

View more
  1 in total

1.  Cancer Risks in Solid Organ Transplant Recipients: Results from a Comprehensive Analysis of 72 Cohort Studies.

Authors:  Zhenyu Huo; Caichen Li; Xin Xu; Fan Ge; Runchen Wang; Yaokai Wen; Haoxin Peng; Xiangrong Wu; Hengrui Liang; Guilin Peng; Run Li; Danxia Huang; Ying Chen; Ran Zhong; Bo Cheng; Shan Xiong; Weiyi Lin; Jianxing He; Wenhua Liang
Journal:  Oncoimmunology       Date:  2020-11-29       Impact factor: 8.110

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.